HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.

about

Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.

P2860

Q50066279-FFDBDC4C-B90D-4BBD-9005-DD26B19D8589 Q50068095-23BCCD1C-1C34-4744-BEBD-3728C373331B

P2860

HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.

Item

http://www.wikidata.org/entity/Q41670053

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

HM71224, a selective Bruton's ...... e development of murine lupus.

@en

type

Item

label

HM71224, a selective Bruton's ...... e development of murine lupus.

@en

prefLabel

HM71224, a selective Bruton's ...... e development of murine lupus.

@en

P1476

HM71224, a selective Bruton's ...... e development of murine lupus.

@en

P2093

Joo-Yun Byun

http://www.w3.org/2001/XMLSchema#string

Ki Tae Park

http://www.w3.org/2001/XMLSchema#string

Kwang Woo Hwang

http://www.w3.org/2001/XMLSchema#string

Kwee Hyun Suh

http://www.w3.org/2001/XMLSchema#string

Kyu Hang Lee

http://www.w3.org/2001/XMLSchema#string

Sun Young Jang

http://www.w3.org/2001/XMLSchema#string

Young Hoon Kim

http://www.w3.org/2001/XMLSchema#string

Young-Mi Lee

http://www.w3.org/2001/XMLSchema#string

Yu-Yon Kim

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

The pathogenesis of systemic lupus erythematosus—an update

Pathogenesis of kidney disease in systemic lupus erythematosus.

Hematological disorders in patients with systemic lupus erythematosus.

Lupus nephritis.

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice

The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets.

P2888

s13075-017-1402-1

P304

211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-017-1402-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091925094

http://www.w3.org/2001/XMLSchema#string

P698

28950886

http://www.w3.org/2001/XMLSchema#string

P932

5615432

http://www.w3.org/2001/XMLSchema#string

HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.

about

P2860

P2860

HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932